The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.

Inclusion Criteria:

• Age ≥ 18 years
• Patients presenting with a solid tumor or a malignant hemopathy,
• Patients treated with or beginning treatment with neutropenia-inducing chemotherapy (regardless of the cycle),
• Patients in whom treatment with Nivestim® is instituted for the purpose of reducing the duration of the neutropenias and the incidence of the chemotherapy-induced febrile neutropenias

Exclusion Criteria:

• Patients presenting with a chronic myeloproliferative syndrome,
• Patients presenting with a myelodysplastic syndrome,
• Patients showing hypersensitivity to any of the ingredients of Nivestim®,
• Patients not receiving chemotherapy,
• Patients who were already included in the study during a previous chemotherapy line

Patients receiving chemotherapy and treated with Nivestim® to prevent or reduce chemotherapy-induced febrile neutropenia.